Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (CogMS)

This study has been completed.
CogState Ltd.
Information provided by (Responsible Party):
Clinique Neuro-Outaouais Identifier:
First received: November 10, 2011
Last updated: March 30, 2015
Last verified: March 2015
This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the CogState battery of tests.

Condition Intervention Phase
Multiple Sclerosis
Other: Observational Cognitive assessments
Other: noninterventional, cognitive testing in tysabri treated patients
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Resource links provided by NLM:

Further study details as provided by Clinique Neuro-Outaouais:

Primary Outcome Measures:
  • SDMT CogState battery [ Time Frame: 2 years ]
    Monthly cognitive assessments

Enrollment: 63
Study Start Date: September 2011
Study Completion Date: March 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
cognitive evolution, observational,MS
multiple sclerosis tysabri treated patients
Other: Observational Cognitive assessments
Other Name: Cognitive assessments
Other: noninterventional, cognitive testing in tysabri treated patients
noninterventional, cognitive testing in Tysabri treated patients

Detailed Description:

Tysabri reduces the relapse frequency, slows progression and preserves cognitive function as compared to placebo as per the AFFIRM trial. The benefit on relapse rate and progression appears to be sustained in longer-term studies such as STRATA. In clinical practice however despite a stable condition on the Expanded Disability Status Scale (EDSS) patients often complain of cognitive deterioration. It has yet to be shown that Tysabri will prevent cognitive deterioration after more than 2 years of treatment.

The Symbol Digit Modalities Test (SDMT) is a sensitive and validated test of cognition in MS. CogState offers a standardized battery of cognitive tests frequently used in clinical research in the fields of dementia and Parkinson's disease. The CogState battery of tests consisting of the Detection test (processing speed), Identification test (attention), One Back test (working memory), International Shopping List test (verbal learning) and the Groton Maze Learning test (reasoning and problem solving) will further confirm and validate the results of the Symbol Digit Modalities Test(SDMT) in MS patients as well as examine other cognitive parameters.

Together the above tests done prospectively can assess the evolution of cognitive function in Tysabri treated MS patients over the longer term.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with multiple sclerosis who are receiving Tysabri per indication.

Inclusion Criteria:

  • Patients with multiple sclerosis who are receiving Tysabri per indication and are willing and able to give an informed consent.

Exclusion Criteria:

  • Patients who are depressed as per the Beck depression questionnaire at screening or at any time during the study.
  • Patients with cognitive decline from causes other than MS.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01658384

Canada, Quebec
Clinique Neuro-Outaouais
Gatineau, Quebec, Canada, J9J 0A5
Sponsors and Collaborators
Clinique Neuro-Outaouais
CogState Ltd.
Principal Investigator: François H Jacques, MD Clinique Neuro-Outaouais and Centre de Santé et de Services Sociaux de Gatineau, Hôpital de Hull
  More Information

Responsible Party: Clinique Neuro-Outaouais Identifier: NCT01658384     History of Changes
Other Study ID Numbers: CNO-001
Study First Received: November 10, 2011
Last Updated: March 30, 2015

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017